Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to filter for deals involving major R&D and commercial rights, namely licensing of biotech, pharmaceutical, medical device, diagnostic, and technology platforms. This gave us an initial set of over 950 deals form January 2017 to August 2018 among the broader set of 12,000+ deals. We then sorted by upfront cash payments, overall deal values, deal counts, and applied our experience in context to produce tables of top companies and their deal totals.
Interesting Takeaways
- The top 10 companies paid over $6.5 billion of the $11 billion-plus in total upfront cash in the 20 months since the beginning of 2017 – 60% of the total from 10 companies.
- This was among 131 deals in the group and $51.3 billion in overall deal value
- We could have added 12 more companies to the list and still see deals with $100 million or more paid up front
DealForma Datasets
- Companies – Large biopharma companies in-licensing or paying for the option to license
- Deals – Development and commercialization deals for technology platforms, preclinical and later compounds (Phase I, Phase II, Phase III, and Approved), medical devices, and diagnostics (full list of criteria in the DealForma platform).
Story Published in Endpoints News: Read the story
Run your own analysis with your DealForma access.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
18,402
Deal Profiles
9,386
Funding Rounds
19,466
Company Profiles
13,866
Product Profiles
119K+
Clinical Trials
3,392
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
More from the DealForma Blog
Life Sciences M&A Tops $240 Billion in 2019
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Cancer Cell Therapy M&A
Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.
Gene Therapy Deals, M&A, and Venture Funding
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Reverse Mergers in Biopharma
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
Biopharma Partnering Sets Records in Q1 2019 after a Strong 2018
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Top 10 Venture Round Investors in Cancer Therapeutics
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A Starts with a Bang in 2019 after Rebounding in 2018
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Oncology Partnering Deal Trends: Early Stage Deals Dominate with Highest Potential Deal Values
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Top Investors in Biotech Venture Rounds
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in?
Biotech Companies in Major Industry Centers Rake in the Cash
Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biotech and pharma, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.
DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.
Company
About Us
Analysis / Blog
Contact Us
Product
Support
Pricing
Connect
Made in San Mateo, CA and around the world support@dealforma.com (650) 353-9363 Terms Privacy
Copyright © 2020 DealForma